These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 3069534)

  • 1. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis.
    Wallensteen M; Dahlquist G; Persson B; Landin-Olsson M; Lernmark A; Sundkvist G; Thalme B
    Diabetologia; 1988 Sep; 31(9):664-9. PubMed ID: 3069534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased reduction in fasting C-peptide is associated with islet cell antibodies in type 1 (insulin-dependent) diabetic patients.
    Marner B; Agner T; Binder C; Lernmark A; Nerup J; Mandrup-Poulsen T; Walldorff S
    Diabetologia; 1985 Dec; 28(12):875-80. PubMed ID: 3912242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors predicting residual beta-cell function in the first year after diagnosis of childhood type 1 diabetes.
    Couper JJ; Hudson I; Werther GA; Warne GL; Court JM; Harrison LC
    Diabetes Res Clin Pract; 1991 Jan; 11(1):9-16. PubMed ID: 2019237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity and reproducibility of urinary C-peptide as estimate of islet B-cell function in insulin-treated diabetes.
    Gjessing HJ; Matzen LE; Faber OK; Frøland A
    Diabet Med; 1989; 6(4):329-33. PubMed ID: 2524338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homogeneity in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr.
    Snorgaard O; Lassen LH; Binder C
    Diabetes Care; 1992 Aug; 15(8):1009-13. PubMed ID: 1505301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effect of islet B-cell function in insulin-treated diabetes.
    Gjessing HJ; Matzen LE; Iversen S; Faber OK; Frøland A
    Scand J Clin Lab Invest; 1989 Jun; 49(4):337-43. PubMed ID: 2662383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin antibodies in diabetic children before treatment: a marker for islet B-cell destruction?
    De Beaufort CE; Binder C; Bruining GJ; Den Boer NC; Van Strik R
    Diabet Med; 1988; 5(5):441-3. PubMed ID: 2970916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus.
    Landin-Olsson M; Nilsson KO; Lernmark A; Sundkvist G
    Diabetologia; 1990 Sep; 33(9):561-8. PubMed ID: 2253834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients.
    Gottsäter A; Landin-Olsson M; Fernlund P; Lernmark A; Sundkvist G
    Diabetes Care; 1993 Jun; 16(6):902-10. PubMed ID: 8325204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seasonality of type 1 (insulin-dependent) diabetes mellitus: values of C-peptide, insulin antibodies and haemoglobin A1c show evidence of a more rapid loss of insulin secretion in epidemic patients.
    Ludvigsson J; Afoke AO
    Diabetologia; 1989 Feb; 32(2):84-91. PubMed ID: 2656353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.
    Chaillous L; Lefèvre H; Thivolet C; Boitard C; Lahlou N; Atlan-Gepner C; Bouhanick B; Mogenet A; Nicolino M; Carel JC; Lecomte P; Maréchaud R; Bougnères P; Charbonnel B; Saï P
    Lancet; 2000 Aug; 356(9229):545-9. PubMed ID: 10950231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships among islet cell antibodies, residual beta-cell function, and metabolic control in patients with insulin-dependent diabetes mellitus of long duration: use of a sensitive C-peptide radioimmunoassay.
    Nakanishi K; Kobayashi T; Miyashita H; Ohkubo M; Sugimoto T; Murase T; Kosaka K; Inouye K; Kono M
    Metabolism; 1990 Sep; 39(9):925-30. PubMed ID: 2202883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Factors affecting C-peptide level during the first year of type 1 diabetes in children].
    Zmysłowska A; Szadkowska A; Andrzejewski W; Wegner O; Wyka K; Młynarski W; Bodalski J
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):103-11. PubMed ID: 15504313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proinsulin immunoreactivity in recent-onset IDDM: the significance of insulin antibodies and insulin autoantibodies.
    Snorgaard O; Kjems LL; Røder ME; Hartling SG; Dinesen B; Binder C
    Diabetes Care; 1996 Feb; 19(2):146-50. PubMed ID: 8718435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children.
    Sochett EB; Daneman D; Clarson C; Ehrlich RM
    Diabetologia; 1987 Jul; 30(7):453-9. PubMed ID: 3311859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry.
    Decochez K; Keymeulen B; Somers G; Dorchy H; De Leeuw IH; Mathieu C; Rottiers R; Winnock F; ver Elst K; Weets I; Kaufman L; Pipeleers DG; Gorus FK;
    Diabetes Care; 2000 Aug; 23(8):1072-8. PubMed ID: 10937500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of delayed beta-cell destruction in type 1 (insulin-dependent) diabetic patients with persisting complement-fixing cytoplasmic islet cell antibodies.
    Mustonen A; Knip M; Huttunen NP; Puukka R; Käär ML; Akerblom HK
    Diabetologia; 1984 Oct; 27(4):421-6. PubMed ID: 6391985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Islet cell antibodies (ICA), insulin autoantibodies (IAA), islet cell surface antibodies (ICSA) and C-peptide in 1031 school children in a population with a high background incidence of IDDM.
    Samuelsson U; Ludvigsson J; Sundkvist G
    Diabetes Res Clin Pract; 1994 Dec; 26(3):155-62. PubMed ID: 7736895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes.
    Gjessing HJ; Matzen LE; Faber OK; Frøland A
    Diabetologia; 1989 May; 32(5):305-11. PubMed ID: 2666217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes.
    Brown RJ; Sinaii N; Rother KI
    Diabetes Care; 2008 Jul; 31(7):1403-4. PubMed ID: 18594062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.